John Libbey Eurotext

European Journal of Dermatology


Pneumocystis jirovecii pneumonia infection in pemphigus patients treated with rituximab: an observational nationwide epidemiological study in Taiwan Volume 28, issue 5, September-October 2018


  • Figure 1


1 Department of Dermatology, Kaohsiung Veterans General Hospital, Kaohsiung, Taiwan
2 IZZ Immunologie-Zentrum Zürich, Zurich, Switzerland
3 Department of Dermatology and Allergy, Technische Universität München, Munich, Germany
4 Department of Medical Education and Research, Kaohsiung Veterans General Hospital, Kaohsiung, Taiwan
5 Center for Big Data Analytics and Statistics, Chang Gung Memorial Hospital, Linkou, Taiwan
a These authors contributed equally

Rituximab is gradually becoming the first-line treatment for pemphigus [1], however, it is debated whether rituximab can increase the risk of Pneumocystis jirovecii pneumonia (PJP) infection [2]. For patients with organ transplants, ANCA-positive vasculitis, and haematological malignancies, there is a high level of mortality and morbidity, and PJP prophylaxis is routinely used for such patients. A delayed diagnosis is common [2], mainly due to vague and non-specific early symptoms and signs [3, 4]. [...]